Nicholas D Klemen, Sinchun Hwang, Martina Bradic, Evan Rosenbaum, Mark A Dickson, Mrinal M Gounder, Ciara M Kelly, Mary L Keohan, Sujana Movva, Katherine A Thornton, Ping Chi, Benjamin A Nacev, Jason E Chan, Edmund K Bartlett, Allison L Richards, Samuel Singer, Mark T A Donoghue, William D Tap, Sandra P D'Angelo
PURPOSE: Programmed cell death protein 1 (PD-1) blockade can mediate objective responses in advanced sarcomas, but their durability has not been established and it is unclear if hyperprogressive disease (HPD) occurs in sarcomas treated with PD-1 inhibitors. EXPERIMENTAL DESIGN: We pooled patients who were treated prospectively with nivolumab or pembrolizumab as monotherapy or with bempegaldesleukin, epacadostat, ipilimumab, or talimogene laherparepvec. We did a new independent assessment for HPD and analyzed clinical, pathologic, and genomic data from baseline tumor biopsies...
March 1, 2022: Clinical Cancer Research